These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 34825155)

  • 1. Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS.
    Cannella R; Dioguardi Burgio M; Beaufrère A; Trapani L; Paradis V; Hobeika C; Cauchy F; Bouattour M; Vilgrain V; Sartoris R; Ronot M
    JHEP Rep; 2021 Dec; 3(6):100380. PubMed ID: 34825155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI imaging features for predicting macrotrabecular-massive subtype hepatocellular carcinoma: a systematic review and meta-analysis.
    Kim TH; Woo S; Lee DH; Do RK; Chernyak V
    Eur Radiol; 2024 Oct; 34(10):6896-6907. PubMed ID: 38507054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease.
    Cao J; Shon A; Yoon L; Kamaya A; Tse JR
    Eur Radiol; 2024 Dec; 34(12):7622-7631. PubMed ID: 38951191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological considerations of CEUS LI-RADS: correlation with fibrosis stage and tumour histological grade.
    Cheng MQ; Hu HT; Huang H; Pan JM; Xian MF; Huang Y; Kuang M; Xie XY; Li W; Wang W; Lu MD
    Eur Radiol; 2021 Aug; 31(8):5680-5688. PubMed ID: 33502556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gd-EOB MRI for HCC subtype differentiation in a western population according to the 5
    Auer TA; Halskov S; Fehrenbach U; Nevermann NF; Pelzer U; Mohr R; Hamm B; Schöning W; Horst D; Ihlow J; Geisel D
    Eur Radiol; 2023 Oct; 33(10):6902-6915. PubMed ID: 37115216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS.
    Hu YX; Shen JX; Han J; Mao SY; Mao RS; Li Q; Li F; Guo ZX; Zhou JH
    Front Oncol; 2021; 11():641195. PubMed ID: 33912456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
    De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M.
    Heo S; Kang HJ; Choi SH; Kim S; Yoo Y; Choi WM; Kim SY; Lee SS
    Eur Radiol; 2024 May; 34(5):2974-2985. PubMed ID: 37848775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS.
    Choi SJ; Choi SH; Kim DW; Kwag M; Byun JH; Won HJ; Shin YM
    J Hepatol; 2023 Mar; 78(3):596-603. PubMed ID: 36402451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
    Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
    AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
    [No Abstract]   [Full Text] [Related]  

  • 11. Fat-containing hepatocellular carcinoma in patients with cirrhosis: proposal of a diagnostic modification regarding enhancement characteristics.
    Delagnes A; Roux M; Vilgrain V; Guiu B; Laurent V; Sutter O; Bricault I; Trillaud H; Aubé C; Paisant A
    Eur Radiol; 2024 Apr; 34(4):2283-2293. PubMed ID: 37816923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of computed tomography and magnetic resonance imaging findings and histopathological features of macrotrabecular-massive hepatocellular carcinoma.
    Gong Q; Zhang Y; Wu T; Du Z; Zhang Y
    Quant Imaging Med Surg; 2023 Jul; 13(7):4633-4640. PubMed ID: 37456331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features.
    Alhasan A; Cerny M; Olivié D; Billiard JS; Bergeron C; Brown K; Bodson-Clermont P; Castel H; Turcotte S; Perreault P; Tang A
    Abdom Radiol (NY); 2019 Feb; 44(2):517-528. PubMed ID: 30167771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
    Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
    Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
    Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
    Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.
    Zhang Y; Tang W; Xie S; Chen J; Zhang L; Rong D; Kuang S; He B; Wang J
    Eur Radiol; 2021 Oct; 31(10):7715-7724. PubMed ID: 33782766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Performance of CT/MRI Liver Imaging Reporting and Data System v2017 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Lee S; Kim SS; Roh YH; Choi JY; Park MS; Kim MJ
    Liver Int; 2020 Jun; 40(6):1488-1497. PubMed ID: 32145134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.
    Fraum TJ; Cannella R; Ludwig DR; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
    Eur Radiol; 2020 Feb; 30(2):996-1007. PubMed ID: 31654212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
    Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
    Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI.
    Moon JY; Min JH; Kim YK; Cha D; Hwang JA; Ko SE; Choi SY; Yun EJ; Kim SW; Won HJ
    Korean J Radiol; 2021 Nov; 22(11):1786-1796. PubMed ID: 34402243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.